CADTH | Evidence Driven
CADTH | Evidence Driven

Velcade for Multiple Myeloma - Details

Details

Files
Generic Name:
Bortezomib
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Janssen
Brand Name:
Velcade
Project Line:
Reimbursement Review
Project Number:
PC0016-000
Strength:
3.5mg/vial
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Cancer Care Ontario Hematology Disease Site Group
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary Provincial Funding Summary View PDF
Bortezomib (Velcade) for Multiple Myeloma - pERC Final Recommendation Final Recommendation March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Final Clinical Guidance Report Guidance Reports March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Final Economic Guidance Report Guidance Reports March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - pERC Initial Recommendation Initial Recommendation March 7, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - PAG Feedback on Initial Recommendation Feedback March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Manufacturer (Janssen) Feedback on Initial Recommendation Feedback March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Submitter (CCOHDSG) Feedback on Initial Recommendation Feedback March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) Feedback on Initial Recommendation Feedback March 25, 2013 View PDF
Bortezomib (Velcade) for Multiple Myeloma - Patient Advocacy Group (Myeloma Canada) COI Declarations Feedback March 25, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 11, 2013